Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

تقرير يلقي الضوء على تأثير الأزمة السورية على المستشفيات الحكومية


The impact of the Syrian crisis on Lebanon has been profound particularly in the healthcare sector. The influx of Syrian refugees has strained the public hospitals and their ability to respond to the crisis, resulting in:
  • An increased demand for healthcare services;
  • An increase in unpaid health services to refugees;
  • A sharp rise in communicable diseases and emergence of new diseases in Lebanon;
  • Increased risks of epidemics such as water-borne diseases, measles, and tuberculosis 1.
Neither United Nations High Commissioner of Refugees (UNHCR) nor other Non-Governmental Organizations (NGO) was able to meet the required level of funding to provide refugees with an acceptable level of secondary and tertiary healthcare services. They, therefore, decided to change their model of response in terms of healthcare support to Syrian refugees. As of 2014, UNHCR started covering 75% instead 85% of the hospitalization cost, leaving the patient with the remaining share of 25% to be paid out of pocket or by a third party. The healthcare referrals covered by UNHCR are limited to deliveries and life-threatening emergencies 2.

Hospitals are overburdened with Syrian patients who are unable to pay their part of the bill (increased to 25% of their total hospital fees) as well as patients whose hospitalizations are not subsidized at all. Some hospitals have put in place strategies to recover as much of the 25% as possible (deposits, retaining IDs/corpses, inflating bills). Referral of uncovered Syrian patients with complicated morbidities to public hospitals has become a common practice by private hospitals.

Overwhelmed by the high demand of healthcare by Syrian refugees, public hospitals end up treating patients without any specific reimbursement scheme thus creating a huge financial burden. This burden adds up to the existing difficult financial situation of public hospitals, putting the whole healthcare sector under stress. Public hospitals are restrained from completing their mission and incapable of providing healthcare services neither to Syrians refugees nor to Lebanese citizens...
    ...
    169
    ...
ATC Name B/G Ingredients Dosage Form Price
A02BC01 GASTRIMUT G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 427,342 L.L
A02BC01 GASTRIMUT G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 6,720,556 L.L
A02BC01 MEDIZOLE GP G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 503,941 L.L
A02BC01 NEOOPRAZOLE G Omeprazole - 20mg 20mg Capsule, hard, gastro-resistant 407,184 L.L
A02BC01 GASTRIMUT G Omeprazole - 40mg 40mg Capsule, hard, gastro-resistant 503,941 L.L
A02BC01 GASTRIMUT G Omeprazole - 40mg 40mg Capsule, hard, gastro-resistant 956,816 L.L
A02BC05 ESO TAD G Esomeprazole - 20mg 20mg Capsule, hard, gastro-resistant 299,677 L.L
A02BC05 ESO TAD G Esomeprazole - 40mg 40mg Capsule, hard, gastro-resistant 389,714 L.L
L04AX07 MAROVAREX G Dimethyl Fumarate - 120mg 120mg Capsule, hard, gastro-resistant 9,838,676 L.L
L04AX07 MAROVAREX G Dimethyl Fumarate - 240mg Capsule, hard, gastro-resistant 60,848,734 L.L
L01EA01 SAGITTA G Imatinib - 400mg 400mg Capsule, hard 51,723,840 L.L
N05AX15 REAGILA G Cariprazine HCl - 1.5mg 1.5mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine HCl - 3mg 3mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine HCl - 4.5mg 4.5mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine - 6mg 6mg Capsule, hard 6,394,003 L.L
L01EA01 SAGITTA G Imatinib - 100mg 100mg Capsule, hard 25,170,264 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 2.5mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 5mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 10mg, Amlodipine - 5mg Capsule, hard 1,358,625 L.L
C09BB07 RAMIPRIL/AMLODIPINE GENERICON G Ramipril - 10mg, Amlodipine - 10mg Capsule, hard 1,358,625 L.L
N03AX12 GABAMOX G Gabapentin - 300mg 300mg Capsule, hard 1,108,670 L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 50mg 50mg Capsule, hard 70,084,833 L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 75mg 75mg Capsule, hard 149,227,143 L.L
N03AX12 GABAMOX G Gabapentin - 400mg 400mg Capsule, hard 1,233,647 L.L
L01ED03 ALECENSA B Alectinib - 150mg 150mg Capsule, hard 490,837,809 L.L
A07XA04 HIDRASEC B Racecadotril - 100mg 100mg Capsule, hard 411,216 L.L
L01EF01 PAPILLIO G Palbociclib - 75mg 75mg Capsule, hard 147,883,080 L.L
N02AA05 OXYNORM B Oxycodone HCl - 5mg 5mg Capsule, hard 1,991,575 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard L.L
N02AA05 OXYNORM B Oxycodone HCl - 10mg 10mg Capsule, hard 3,988,525 L.L
    ...
    169
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025